Stock DCAL DISHMAN CARBOGEN AMCIS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dishman Carbogen Amcis Limited Bombay S.E.

Equities

DCAL

INE385W01011

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:48 2024-05-09 EDT 		5-day change 1st Jan Change
197 INR -4.97% Intraday chart for Dishman Carbogen Amcis Limited -15.17% +15.37%
04-01 Dishman Carbogen Amcis Limited Announces Board Cessations CI
03-19 Dishman Carbogen Amcis Arm Gets GMP Certificate from Brazilian Authority for Shanghai Site MT

Valuation

Fiscal Period: Marzo 2018 2019 2020 2021 2022 2023
Capitalization 1 51,703 33,626 8,369 17,089 28,966 19,559
Enterprise Value (EV) 1 61,052 43,080 19,658 29,078 43,237 38,560
P/E ratio 33.4 x 16 x 4.76 x -10.3 x 161 x -65.6 x
Yield - 0.1% - - - -
Capitalization / Revenue 3 x 1.63 x 0.41 x 0.89 x 1.35 x 0.81 x
EV / Revenue 3.54 x 2.09 x 0.96 x 1.52 x 2.02 x 1.6 x
EV / EBITDA 15.3 x 7.49 x 3.92 x 11.7 x 14.9 x 11.7 x
EV / FCF -149 x -53.1 x 85 x -338 x -27.5 x -18.9 x
FCF Yield -0.67% -1.88% 1.18% -0.3% -3.64% -5.3%
Price to Book 1.01 x 0.63 x 0.15 x 0.3 x 0.52 x 0.34 x
Nbr of stocks (in thousands) 161,394 161,394 156,863 156,783 156,783 156,783
Reference price 2 320.4 208.4 53.35 109.0 184.8 124.8
Announcement Date 18-08-27 19-08-29 20-09-01 21-06-25 22-09-06 23-09-04
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Marzo 2018 2019 2020 2021 2022 2023
Net sales 1 17,230 20,586 20,436 19,120 21,407 24,129
EBITDA 1 3,987 5,751 5,021 2,480 2,899 3,303
EBIT 1 2,797 4,236 3,463 709.1 1,185 1,517
Operating Margin 16.23% 20.58% 16.95% 3.71% 5.54% 6.29%
Earnings before Tax (EBT) 1 2,308 3,088 2,221 -650.3 -42.5 -545.9
Net income 1 1,546 2,103 1,803 -1,651 180.1 -298
Net margin 8.97% 10.22% 8.82% -8.64% 0.84% -1.24%
EPS 2 9.577 13.03 11.20 -10.53 1.149 -1.901
Free Cash Flow 1 -409.6 -812 231.4 -85.95 -1,574 -2,043
FCF margin -2.38% -3.94% 1.13% -0.45% -7.35% -8.47%
FCF Conversion (EBITDA) - - 4.61% - - -
FCF Conversion (Net income) - - 12.83% - - -
Dividend per Share - 0.2000 - - - -
Announcement Date 18-08-27 19-08-29 20-09-01 21-06-25 22-09-06 23-09-04
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: Marzo 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4
Net sales 1 4,686 5,293 5,507 4,589 5,621 5,690 5,406 6,140 6,398 6,186
EBITDA 1 626.1 883.6 1,006 992.3 1,085 219.9 882.9 786 1,139 514.4
EBIT - - - - - - - - - -
Operating Margin - - - - - - - - - -
Earnings before Tax (EBT) - - - - - - - - - -
Net income -160.7 -1,350 - - - - - - - -
Net margin -3.43% -25.51% - - - - - - - -
EPS - - - - - - - - - -
Dividend per Share - - - - - - - - - -
Announcement Date 21-02-11 21-05-11 21-08-12 21-10-28 22-02-03 22-05-10 22-08-09 22-11-11 23-02-11 23-05-23
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: Marzo 2018 2019 2020 2021 2022 2023
Net Debt 1 9,350 9,453 11,289 11,989 14,271 19,001
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 2.345 x 1.644 x 2.248 x 4.835 x 4.923 x 5.752 x
Free Cash Flow 1 -410 -812 231 -86 -1,574 -2,043
ROE (net income / shareholders' equity) 3.12% 4.01% 3.24% -2.89% 0.32% -0.52%
ROA (Net income/ Total Assets) 2.54% 3.65% 2.78% 0.54% 0.87% 1.05%
Assets 1 60,878 57,623 64,772 -307,849 20,673 -28,424
Book Value Per Share 2 316.0 333.0 366.0 363.0 354.0 371.0
Cash Flow per Share 2 4.060 4.730 7.770 15.50 7.030 8.410
Capex 1 2,165 3,081 4,086 3,660 4,638 5,741
Capex / Sales 12.56% 14.97% 19.99% 19.14% 21.67% 23.79%
Announcement Date 18-08-27 19-08-29 20-09-01 21-06-25 22-09-06 23-09-04
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.95% 698B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.97% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.83% 328B
ABBVIE INC. Stock AbbVie Inc.
+3.54% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.02% 238B
NOVARTIS AG Stock Novartis AG
+6.68% 203B
ROCHE HOLDING AG Stock Roche Holding AG
-9.08% 198B
AMGEN INC. Stock Amgen Inc.
+6.70% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. DCAL Stock
  4. DCAL Stock
  5. Financials Dishman Carbogen Amcis Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW